Ignite Creation Date:
2024-05-05 @ 12:01 PM
Last Modification Date:
2024-10-26 @ 9:18 AM
Study NCT ID:
NCT00212355
Status:
COMPLETED
Last Update Posted:
2019-04-24
First Post:
2005-09-13
Brief Title:
Efficacy and Safety Long-term Study of Zinc Acetate to Treat Wilsons Disease in Japan
Sponsor:
Nobelpharma
Organization:
Nobelpharma
Study Overview
Official Title:
Phase3 Open-Label Clinical Trial of Zinc Acetate for Treatment of Wilsons Disease in Japan
Status:
COMPLETED
Status Verified Date:
2019-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this long-term study is to determine whether Zinc Acetate is effective and safe in the treatment of Wilsons disease among Japanese
Detailed Description:
Wilson disease is an autosomal recessive disorder with copper metabolism In Japan the standard treatment is the use of copper chelating agents such as D-penicillamine and trientine In this study we investigate efficacy on zinc acetate in Japanese patients with Wilson disease
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None